GPA33
Cell surface A33 antigen
Also known as: A33, GPA33_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q99795
- Gene
- GPA33
- Ensembl
- ENSG00000143167
- Chromosome
- 1
- Canonical length
- 319 aa
- Protein class
- Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
OverviewNCBI Gene
The glycoprotein encoded by this gene is a cell surface antigen that is expressed in greater than 95% of human colon cancers. The open reading frame encodes a 319-amino acid polypeptide having a putative secretory signal sequence and 3 potential glycosylation sites. The predicted mature protein has a 213-amino acid extracellular region, a single transmembrane domain, and a 62-amino acid intracellular tail. The sequence of the extracellular region contains 2 domains characteristic of the CD2 subgroup of the immunoglobulin (Ig) superfamily. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
319 residues, UniProt reviewed canonical sequence.
>Q99795|GPA33
1 MVGKMWPVLW TLCAVRVTVD AISVETPQDV LRASQGKSVT LPCTYHTSTS SREGLIQWDK
61 LLLTHTERVV IWPFSNKNYI HGELYKNRVS ISNNAEQSDA SITIDQLTMA DNGTYECSVS
121 LMSDLEGNTK SRVRLLVLVP PSKPECGIEG ETIIGNNIQL TCQSKEGSPT PQYSWKRYNI
181 LNQEQPLAQP ASGQPVSLKN ISTDTSGYYI CTSSNEEGTQ FCNITVAVRS PSMNVALYVG
241 IAVGVVAALI IIGIIIYCCC CRGKDDNTED KEDARPNREA YEEPPEQLRE LSREREEEDD
301 YRQEEQRSTG RESPDHLDQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GPA33 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.4
- Highest tissue expression
- 202 nTPM
Expression across tissuesHPA
Tissue
- colon: 202 nTPM
- rectum: 184 nTPM
- duodenum: 141 nTPM
- small intestine: 129 nTPM
- appendix: 18 nTPM
- lung: 6.7 nTPM
Single-cell type
- cardiomyocytes: 797 nCPM
- colonocytes: 636 nCPM
- enterocytes: 297 nCPM
- goblet cells: 293 nCPM
- enteric transient amplifying cells: 131 nCPM
- myonuclei: 87 nCPM
Immune cell
- naive CD4 T-cell: 24 nTPM
- T-reg: 20 nTPM
- memory CD4 T-cell: 11 nTPM
- total PBMC: 6.8 nTPM
- memory CD8 T-cell: 5.7 nTPM
- intermediate monocyte: 3.8 nTPM
Brain region
- choroid plexus: 0.9 nTPM
- hypothalamus: 0.5 nTPM
- thalamus: 0.5 nTPM
- cerebral cortex: 0.4 nTPM
- pons: 0.3 nTPM
- midbrain: 0.2 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.07
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.01
- DepMap mean gene effect
- -0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GPA33 as an antibody target. Whether an autoantibody or antibody against GPA33 could matter depends on whether native GPA33 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GPA33 is annotated at the cell surface, where native GPA33 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label GPA33 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...